Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Iron overload in steatotic hepatocytes drives systemic metabolic dysfunction via alterations in hepatokine production
Hye Jin Jo, Ayoung Kim, Hyunsoo Rho, Ae Kyung Park, Gil-Hwan Kim, Seo Jeong Jo, Hao Yuxin, You-Jung Hong, Ji Min Yeon, Hwang Chan Yu, Mi-Young Song, Jeongwoo Park, Yeon Hee Jeong, Sung Eun Hong, Hyo Jin Yeon, Da Young Oh, Philipp E. Scherer, Cheol Soo Choi, Dong Hyeon Lee, Sung Hwan Ki, Keon Wook Kang, Murim Choi, Byung-Hyun Park, Eun Ju Bae, Sang Geon Kim, Won Kim, Chang Yeob Han
Hye Jin Jo, Ayoung Kim, Hyunsoo Rho, Ae Kyung Park, Gil-Hwan Kim, Seo Jeong Jo, Hao Yuxin, You-Jung Hong, Ji Min Yeon, Hwang Chan Yu, Mi-Young Song, Jeongwoo Park, Yeon Hee Jeong, Sung Eun Hong, Hyo Jin Yeon, Da Young Oh, Philipp E. Scherer, Cheol Soo Choi, Dong Hyeon Lee, Sung Hwan Ki, Keon Wook Kang, Murim Choi, Byung-Hyun Park, Eun Ju Bae, Sang Geon Kim, Won Kim, Chang Yeob Han
View: Text | PDF
Research In-Press Preview Hepatology Metabolism

Iron overload in steatotic hepatocytes drives systemic metabolic dysfunction via alterations in hepatokine production

  • Text
  • PDF
Abstract

Iron overload has emerged as a significant risk factor for metabolic dysfunction-associated steatotic liver disease (MASLD), a growing global health concern. Despite this association, the precise mechanisms by which hepatic iron and its regulatory genes connect liver pathology to systemic metabolic dysfunction remain elusive. Here, we demonstrate that humoral signals originating from iron-overloaded hepatocytes act as critical mediators driving systemic metabolic dysfunction in MASLD. Ferroportin (FPN, SLC40A1), the sole cellular iron exporter, exhibits markedly reduced expression in hepatocytes of both human patients and mouse models with MASLD, concomitant with hepatic iron accumulation. Functionally, hepatocyte-specific FPN deletion significantly exacerbates diet-induced obesity and insulin resistance, with these metabolic perturbations accompanied by decreased energy expenditure and impaired thermogenic capacity. Mechanistically, we establish that hepatic iron accumulation resulting from FPN deficiency enhances the production of two specific hepatokines, Fetuin-A and LECT2, through activation of the transcription factor FoxO1. Notably, therapeutic interventions — including genetic silencing of these hepatokines, hepatocyte-specific FPN overexpression, or oral iron chelation — effectively reverse the metabolic dysfunction phenotypes. These findings provide critical insights into the pathophysiological mechanisms linking MASLD to systemic metabolic disorders and highlight promising therapeutic strategies to combat these diseases.

Authors

Hye Jin Jo, Ayoung Kim, Hyunsoo Rho, Ae Kyung Park, Gil-Hwan Kim, Seo Jeong Jo, Hao Yuxin, You-Jung Hong, Ji Min Yeon, Hwang Chan Yu, Mi-Young Song, Jeongwoo Park, Yeon Hee Jeong, Sung Eun Hong, Hyo Jin Yeon, Da Young Oh, Philipp E. Scherer, Cheol Soo Choi, Dong Hyeon Lee, Sung Hwan Ki, Keon Wook Kang, Murim Choi, Byung-Hyun Park, Eun Ju Bae, Sang Geon Kim, Won Kim, Chang Yeob Han

×

Full Text PDF


Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts